HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Gino Gerosa Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by di Marco, F. Articles by Gerosa, G. Search for Related Content PubMed PubMed Citation Articles by di Marco, F. Articles by Gerosa, G.

J Thorac Cardiovasc Surg 2007;133:1597-1603
© 2007 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety

^a Department of Cardiologic, Thoracic and Vascular Sciences, Division of Cardiac Surgery, Padua University Medical School, Padova, Italy
^b Neurology Division, Padua University Medical School, Padova, Italy.

Received for publication July 25, 2006; revisions received October 17, 2006; accepted for publication December 6, 2006.

^_* Address for reprints: Dr Gino Gerosa, Department of Cardiologic, Thoracic and Vascular Sciences, Division of Cardiac surgery, Padua University Medical School, Via Giustiniani 2, 35100 Padova, Italy. (Email: gino.gerosa{at}unipd.it).

Objective: The main advantage of bioprostheses, avoidance of anticoagulant therapy, is compromised during the early postoperative period; in fact, warfarin is often administered during the first 3 postoperative months.

Methods: We analyzed 250 patients undergoing tissue aortic valve replacement between January 2002 and December 2005. The patients received either aspirin (group 1) or oral anticoagulation (group 2) during the first 3 months. In a subgroup of these patients, we investigated the possible presence of clinically silent microembolization by means of transcranial Doppler for microembolic signal detection.

Results: Thirty-day mortality was 0%. No major neurologic events occurred. Two episodes of bleeding were observed in both groups. Follow-up time was 24 ± 14 months. Overall late mortality rate was 0.8% in group 1 versus 12% (mainly cancer related) in group 2. In group 2, 2 deaths were due to major ischemic neurologic events; overall, 3 major neurologic episodes occurred (international normalized ratio was within therapeutic range). There were no neurologic events in group 1 (P = .12). Stroke-free survival did not reach statistical significance between the 2 groups. Transcranial Doppler was performed after a mean interval of 55 ± 19 days, with no detection of microembolic signals in patients receiving either aspirin or warfarin. There were no episodes of bleeding or neurologic events.

Conclusions: Aspirin therapy appears to be the appropriate response to both cardiac surgeons’ and patients’ needs in the early postoperative course after aortic valve replacement with tissue valves, demonstrating adequate antithromboembolic efficacy with no added risk for bleeding as well as ease of administration.

This article has been cited by other articles:

				A. Colli, J.-P. Verhoye, R. Heijmen, J. T. Strauch, J. A. J. Hyde, D. Pagano, M. Antunes, H. Koertke, S. K. Ohri, D. H. L. Bail, et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results Eur J Cardiothorac Surg, April 1, 2008; 33(4): 531 - 536. [Abstract] [Full Text] [PDF]

				M. Pocar, D. Passolunghi, A. Moneta, and F. Donatelli Primary and redo valve replacement before and after liver transplantation Eur J Cardiothorac Surg, October 1, 2007; 32(4): 674 - 675. [Abstract] [Full Text] [PDF]